Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
BGB-290
DRUG
2 trials
Sponsors
BeiGene
Conditions
For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment
HER2-negative Breast Cancer
Phase 1
Phase 1a/1b BGB-290 for Advanced Solid Tumors.
Completed
NCT02361723
BeiGene
For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment
Start: 2014-07-03
End: 2019-09-03
Updated: 2024-12-27
Phase 2
Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China
Completed
NCT03575065
BeiGene
HER2-negative Breast Cancer
Start: 2018-06-22
End: 2021-04-14
Updated: 2024-10-26
Related Papers
Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors
Cancer Medicine
2024-07-01
7 citations
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
Breast Cancer Research and Treatment
2022-12-02
23 citations
Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
British Journal of Cancer
2021-11-18
11 citations
A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline <i>BRCA</i> mutation.
Journal of Clinical Oncology
2021-05-20
9 citations
PARALLEL 303: Phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients (pts) with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line (1L) chemotherapy.
Journal of Clinical Oncology
2021-05-20
1 citations
Human Mass Balance and Metabolite Profiling of [<sup>14</sup>C]‐Pamiparib, a Poly (ADP‐Ribose) Polymerase Inhibitor, in Patients With Advanced Cancer
Clinical Pharmacology in Drug Development
2021-04-19
9 citations
Pamiparib dose escalation in Chinese patients with non‐mucinous high‐grade ovarian cancer or advanced triple‐negative breast cancer
Cancer Medicine
2020-10-31
19 citations
Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or <i>BRCA</i> defects: A trial in progress.
Journal of Clinical Oncology
2019-05-20
5 citations
A phase II trial in progress: Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer and a circulating tumor cell homologous recombination deficiency (HRD) phenotype or <i>BRCA</i> defects.
Journal of Clinical Oncology
2019-03-01
A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer (GC) that responded to platinum-based first-line chemotherapy.
Journal of Clinical Oncology
2019-01-29
5 citations
ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM)
Neuro-Oncology
2018-11-01
7 citations
A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy
Annals of Oncology
2018-10-01
2 citations
Pamiparib, a novel PARP 1/2 inhibitor, monotherapy for gBRCAm patients with recurrent ovarian, fallopian, and primary peritoneal cancer: An open-label, multicenter, phase II trial in China
Annals of Oncology
2018-10-01
2 citations
Preliminary results of pamiparib (BGB-290), a PARP1/2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumors
Annals of Oncology
2018-10-01
2 citations
Abstract CT050: A phase I dose escalation study of BGB-290 in Chinese subjects with advanced ovarian, fallopian, and primary peritoneal, or advanced triple-negative breast cancer
Cancer Research
2018-07-01
1 citations
A phase 3, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy - Trial in progress
Annals of Oncology
2018-06-01
A phase 3, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy.
Journal of Clinical Oncology
2018-05-20
4 citations
A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors.
Journal of Clinical Oncology
2016-05-20
8 citations